| Literature DB >> 28586059 |
Zhuangchen Zhu1, Guang Chen1, Wei Jiao1, Defeng Wang1, Yan Cao1, Qingfu Zhang1, Junqin Wang1.
Abstract
Intervertebral disc (IVD) degeneration is a pathological process, which may lead to lower back pain. The present study aimed to investigate the pathogenesis of IVD degeneration. GSE42611 was downloaded from Gene Expression Omnibus, including 4 nucleus pulposus samples isolated from degenerated IVDs and 4 nucleus pulposus samples separated from normal IVDs. The differentially expressed genes (DEGs) between the degenerated and normal samples were screened using the limma package in R. Functional and pathway enrichment analyses were conducted separately for the upregulated and downregulated genes, using Database for Annotation, Visualization and Integrated Discovery software. In addition, protein‑protein interaction (PPI) networks were constructed using the Search Tool for the Retrieval of Interacting Genes database and Cytoscape software. Finally, module analyses were conducted for the PPI networks using the MCODE plug‑in in Cytoscape. A total of 558 DEGs were identified in the degenerated nucleus pulposus cells: 253 upregulated and 305 downregulated. Pathway enrichment analysis revealed that downregulated thrombospondin 1 (THBS1) was enriched in extracellular matrix‑receptor interaction. Interleukin (IL)‑6 in the PPI network for the upregulated genes and vascular endothelial growth factor A (VEGFA) in the PPI network for the downregulated genes had higher degrees. Additionally, four modules (µM1, µM2, µM3 and µM4) were identified from the PPI network for the upregulated genes. Four modules (dM1, dM2, dM3 and dM4) were identified from the PPI network for the downregulated genes. In the dM2 module, collagen genes and integrin subunit α4 (ITGA4) may interact with each other. Additionally, functional enrichment indicated that collagen genes were enriched in extracellular matrix organization. In conclusion, IL‑6, VEGFA, THBS1, ITGA4 and collagen genes may contribute to the progression of IVD degeneration. These results suggested that the manipulation of these genes and their products may have potential as a novel therapeutic strategy for the treatment of patients with IVD.Entities:
Mesh:
Year: 2017 PMID: 28586059 PMCID: PMC5482069 DOI: 10.3892/mmr.2017.6662
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
The top 10 enriched functions for the differentially expressed genes in the degenerated nucleus pulposus cells
| A, Top 10 functions enriched for the upregulated genes in the degenerated nucleus pulposus cells | ||||
|---|---|---|---|---|
| ID | Description | P-value | Number of genes | Gene |
| GO:0009611 | Response to wounding | 2.35×10−8 | 24 | |
| GO:0006954 | Inflammatory response | 5.99×10−8 | 17 | |
| GO:0010033 | Response to organic substance | 1.56×10−7 | 35 | |
| GO:0006952 | Defense response | 1.68×10−7 | 22 | |
| GO:0042311 | Vasodilation | 2.48×10−6 | 7 | |
| GO:0034097 | Response to cytokine stimulus | 3.62×10−6 | 11 | |
| GO:0009719 | Response to endogenous stimulus | 4.73×10−6 | 24 | |
| GO:0009725 | Response to hormone stimulus | 8.64×10−6 | 22 | |
| GO:0055066 | Di-, tri-valent inorganic cation homeostasis | 1.15×10−5 | 14 | |
| GO:0055080 | Cation homeostasis | 1.82×10−5 | 15 | |
| B, Top 10 enriched functions for the downregulated genes in the degenerated nucleus pulposus cells | ||||
| ID | Description | P-value | Number of genes | Gene |
| GO:0000279 | M phase | 9.18×10−12 | 21 | |
| GO:0048545 | Response to steroid hormone stimulus | 2.95×10−9 | 23 | |
| GO:0009628 | Response to abiotic stimulus | 1.09×10−8 | 26 | |
| GO:0022610 | Biological adhesion | 1.23×10−8 | 28 | |
| GO:0007155 | Cell adhesion | 1.23×10−8 | 28 | |
| GO:0051301 | Cell division | 2.09×10−8 | 16 | |
| GO:0022402 | Cell cycle process | 2.49×10−8 | 24 | |
| GO:0030199 | Collagen fibril organization | 4.36×10−8 | 8 | |
| GO:0007049 | Cell cycle | 4.42×10−8 | 27 | |
Enriched pathways for the differentially expressed genes in the degenerated nucleus pulposus cells.
| A, Pathways enriched for the upregulated genes | ||||
|---|---|---|---|---|
| ID | Description | P-value | Number of genes | Gene |
| rno04060 | Cytokine-cytokine receptor interaction | 2.86×10−4 | 12 | |
| rno04210 | Apoptosis | 3.95×10−4 | 8 | |
| rno04062 | Chemokine signaling pathway | 1.60×10−3 | 10 | |
| rno04621 | NOD-like receptor signaling pathway | 3.04×10−3 | 6 | |
| rno04630 | Jak-STAT signaling pathway | 6.77×10−3 | 8 | |
| rno04620 | Toll-like receptor signaling pathway | 1.45×10−2 | 6 | |
| rno05200 | Pathways in cancer | 3.02×10−2 | 11 | |
| rno00230 | Purine metabolism | 3.71×10−2 | 7 | |
| rno05222 | Small cell lung cancer | 4.41×10−2 | 5 | |
| B, Pathways enriched for the downregulated genes | ||||
| rno04512 | ECM-receptor interaction | 1.17×10−11 | 16 | |
| rno04510 | Focal adhesion | 1.90×10−9 | 20 | |
| rno04640 | Hematopoietic cell lineage | 3.12×10−3 | 7 | |
| rno05200 | Pathways in cancer | 5.58×10−3 | 14 | |
| rno04670 | Leukocyte transendothelial migration | 1.97×10−2 | 7 | |
| rno05219 | Bladder cancer | 2.86×10−2 | 4 | |
| rno04110 | Cell cycle | 2.93×10−2 | 7 | |
| rno04115 | p53 signaling pathway | 3.38×10−2 | 5 | |
| rno04610 | Complement and coagulation cascades | 4.07×10−2 | 5 | |
| rno03320 | PPAR signaling pathway | 4.25×10−2 | 5 | |
Figure 1.Protein-protein interaction network constructed for the upregulated genes.
Figure 2.Protein-protein interaction network constructed for the downregulated genes.
Figure 3.Four modules (µM1, µM2, µM3 and µM4) identified from the protein-protein interaction network constructed for the upregulated genes.
Figure 4.Four modules (dM1, dM2, dM3 and dM4) identified from the protein-protein interaction network constructed for the downregulated genes.
Top 5 functions and pathways enriched for the upregulated genes in µM1, µM2, µM3 and µM4 modules.
| A, Top 5 functions enriched for the upregulated genes in µM1, µM2, µM3 and µM4 modules | |||||
| Module | ID | Description | P-value | Number of genes | Gene |
|---|---|---|---|---|---|
| µM1 | GO:0042330 | Taxis | 1.03×10−8 | 5 | |
| GO:0006935 | Chemotaxis | 1.03×10−8 | 5 | ||
| GO:0006952 | Defense response | 3.82×10−8 | 6 | ||
| GO:0007626 | Locomotory behavior | 4.20×10−7 | 5 | ||
| GO:0006954 | Inflammatory response | 4.97×10−7 | 5 | ||
| µM2 | GO:0010033 | Response to organic substance | 1.21×10−4 | 6 | |
| GO:0042127 | Regulation of cell proliferation | 5.31×10−4 | 5 | ||
| GO:0010035 | Response to inorganic substance | 5.55×10−4 | 4 | ||
| GO:0007167 | Enzyme-linked receptor protein signaling pathway | 6.31×10−4 | 4 | ||
| GO:0031667 | Response to nutrient levels | 6.44×10−4 | 4 | ||
| µM3 | GO:0034097 | Response to cytokine stimulus | 5.04×10−4 | 3 | |
| GO:0009719 | Response to endogenous stimulus | 1.26×10−2 | 3 | ||
| GO:0006508 | Proteolysis | 2.26×10−2 | 3 | ||
| GO:0010033 | Response to organic substance | 3.18×10−2 | 3 | ||
| GO:0007568 | Aging | 4.87×10−2 | 2 | ||
| µM4 | GO:0048878 | Chemical homeostasis | 1.22×10−3 | 4 | |
| GO:0043619 | Regulation of transcription from RNA polymerase II promoter in response to oxidative stress | 2.48×10−3 | 2 | ||
| GO:0043618 | Regulation of transcription from RNA polymerase II promoter in response to stress | 2.97×10−3 | 2 | ||
| GO:0043620 | Regulation of transcription in response to stress | 2.97×10−3 | 2 | ||
| GO:0042592 | Homeostatic process | 3.58×10−3 | 4 | ||
| B, Pathways enriched for the upregulated genes in µM1 and µM2 modules | |||||
| Module | ID | Description | P-value | Number of genes | Gene |
| µM1 | rno04062 | Chemokine signaling pathway | 1.10×10−4 | 4 | |
| rno04621 | NOD-like receptor signaling pathway | 4.36×10−2 | 2 | ||
| µM2 | rno04630 | Jak-STAT signaling pathway | 7.69×10−4 | 4 | |
| µM2 | rno04060 | Cytokine-cytokine receptor interaction | 2.12×10−3 | 4 | |
| rno04620 | Toll-like receptor signaling pathway | 6.74×10−3 | 3 | ||
| rno05200 | Pathways in cancer | 8.17×10−3 | 4 | ||
Top 5 functions and pathways enriched for the downregulated genes in dM1, dM2, dM3 and dM4 modules.
| A, Top 5 functions enriched for the downregulated genes | |||||
|---|---|---|---|---|---|
| Module | ID | Description | P-value | Number of genes | Gene |
| dM1 | GO:0000279 | M phase | 2.70×10−16 | 12 | |
| GO:0007049 | Cell cycle | 6.52×10−15 | 14 | ||
| GO:0022403 | Cell cycle phase | 7.11×10−15 | 12 | ||
| GO:0022402 | Cell cycle process | 1.48×10−14 | 13 | ||
| GO:0000087 | M phase of mitotic cell cycle | 1.70×10−14 | 10 | ||
| dM2 | GO:0030199 | Collagen fibril organization | 5.72×10−10 | 5 | |
| GO:0030198 | Extracellular matrix organization | 1.79×10−7 | 5 | ||
| GO:0043588 | Skin development | 6.89×10−7 | 4 | ||
| GO:0043062 | Extracellular structure organization | 1.10×10−6 | 5 | ||
| GO:0001501 | Skeletal system development | 1.45×10−5 | 5 | ||
| dM3 | GO:0007186 | G-protein coupled receptor protein signaling pathway | 7.27×10−4 | 6 | |
| GO:0007610 | Behavior | 7.91×10−4 | 4 | ||
| GO:0002430 | Complement receptor mediated signaling pathway | 9.92×10−4 | 2 | ||
| GO:0007204 | Elevation of cytosolic calciumion concentration | 1.03×10−3 | 3 | ||
| GO:0051480 | Cytosolic calcium ion homeostasis | 1.29×10−3 | 3 | ||
| dM4 | GO:0042060 | Wound healing | 1.56×10−4 | 4 | |
| GO:0040007 | Growth | 2.91×10−4 | 4 | ||
| GO:0042246 | Tissue regeneration | 3.74×10−4 | 3 | ||
| GO:0007167 | enzyme linked receptor protein signaling pathway | 6.31×10−4 | 4 | ||
| GO:0051094 | Positive regulation of developmental process | 8.57×10−4 | 4 | ||
| dM1 | rno04110 | Cell cycle | 4.40×10-5 | 4 | CCNB1, PLK1, BUB1B, CCNA2 |
| rno04914 | Progesterone-mediated oocyte maturation | 1.41×10-3 | 3 | CCNB1, PLK1, CCNA2 | |
| B, Pathways enriched for the downregulated genes | |||||
| Module | ID | Description | P-value | Number of genes | Gene |
| dM2 | rno04512 | ECM-receptor interaction | 1.37×10−15 | 9 | |
| rno04510 | Focal adhesion | 1.91×10−12 | 9 | ||
| dM3 | rno04080 | Neuroactive ligand-receptor interaction | 9.49×10−4 | 4 | |
| dM4 | rno05200 | Pathways in cancer | 5.33×10−3 | 4 | |
| rno04510 | Focal adhesion | 2.26×10−2 | 3 | ||